Anti-CD52 Therapy in Experimental Autoimmune Encephalomyelitis

被引：0
|
作者：
Turner, Michael J.
Chretien, Nathalie
Havari, Evis
LaMorte, Michael
Roberts, Bruce
Kaplan, Johanne
Siders, William M.
机构：
来源：
ANNALS OF NEUROLOGY | 2012年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
下载
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [11] Anti-CD52 monoclonal antibody: improvement of therapy results in chronic lymphocytic leukemia
    Volkova, M. A.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2006, 51 (02): : 27 - 33
  • [12] Quantification of CD52 antigen expression by normal and leukemic lymphoid cells:: Indications for anti-CD52 antibody therapy?
    Guarini, A
    De Propris, MS
    Intoppa, S
    Milani, ML
    Lisci, A
    Martinelli, M
    Vitale, A
    Mauro, FR
    Foà, R
    BLOOD, 2005, 106 (11) : 60B - 60B
  • [13] Engineering an anti-CD52 antibody for enhanced deamidation stability
    Qiu, Huawei
    Wei, Ronnie
    Jaworski, Julie
    Boudanova, Ekaterina
    Hughes, Heather
    VanPatten, Scott
    Lund, Anders
    Day, Jaime
    Zhou, Yanfeng
    McSherry, Tracey
    Pan, Clark Q.
    Sendak, Rebecca
    MABS, 2019, 11 (07) : 1266 - 1275
  • [14] IMPORTANCE OF IMMUNOGLOBULIN ISOTYPE IN THERAPY OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH MONOCLONAL ANTI-CD4 ANTIBODY
    WALDOR, MK
    MITCHELL, D
    KIPPS, TJ
    HERZENBERG, LA
    STEINMAN, L
    JOURNAL OF IMMUNOLOGY, 1987, 139 (11): : 3660 - 3664
  • [15] Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders - A review
    Pangalis, GA
    Dimopoulou, MN
    Angelopoulou, MK
    Tsekouras, C
    Vassilakopoulos, TP
    Vaiopoulos, G
    Siakantaris, MP
    MEDICAL ONCOLOGY, 2001, 18 (02) : 99 - 107
  • [16] Anti-Inflammatory Effect of Erythropoietin Therapy on Experimental Autoimmune Encephalomyelitis
    Zhang, Xiang
    Li, Qin-Ying
    Xiao, Bao-Guo
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2012, 122 (05) : 255 - 262
  • [17] Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
    Li, Z.
    Richards, S.
    Surks, H. K.
    Jacobs, A.
    Panzara, M. A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 194 (03): : 295 - 314
  • [18] Enhanced potency of glycoengineered anti-CD52 monoclonal antibodies (MAbs)
    Dyer, MJS
    Moser, S
    Briinker, P
    Bird, P
    Almond, N
    Pijentener, U
    Wheat, LMW
    Bolam, E
    Berrie, E
    Grau, R
    Buckby, E
    Kennedy, B
    Stebbings, R
    Hale, G
    Umana, P
    BLOOD, 2005, 106 (11) : 830A - 830A
  • [19] Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disordersA review
    G. A. Pangalis
    M. N. Dimopoulou
    M. K. Angelopoulou
    Ch. Tsekouras
    T. P. Vassilakopoulos
    G. Vaiopoulos
    M. P. Siakantaris
    Medical Oncology, 2001, 18 : 99 - 107
  • [20] Place of monoclonal antibodies (anti-CD52, anti-CD20) in chronic lymphocytic leukemia
    Divine, Marine
    HEMATOLOGIE, 2006, 12 : 35 - 38
12345